Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination

Journal of Immunology

Volumn 181, Issue 12, 2008, Pages 8776-8783

  Miura, Kazutoyo ^a   Zhou, Hong ^a   Moretz, Samuel E ^a   Diouf, Ababacar ^a   Thera, Mahamadou A ^b   Dolo, Amagana ^b   Doumbo, Ogobara ^b   Malkin, Elissa ^a,d   Diemert, David ^a,e   Miller, Louis H ^a   Mullen, Gregory E D ^a,f   Long, Carole A ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF BAMAKO   (Mali)

^c Twinbrook 3 ^*  (United States)

^d PATH Malaria Vaccine Initiative   (United States)

^e Albert B Sabin Vaccine Institute   (United States)

^f ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; APICAL MEMBRANE ANTIGEN 1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CHILD; CLINICAL TRIAL; FEMALE; GROWTH INHIBITION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MALI; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; UNITED STATES; VACCINATION; ANIMAL; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INNATE IMMUNITY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PARASITOLOGY; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INFANT; LONGITUDINAL STUDIES; MALARIA VACCINES; MALARIA, FALCIPARUM; MALI; MEMBRANE PROTEINS; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SINGLE-BLIND METHOD; UNITED STATES;

EID: 58849117152     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.12.8776     Document Type: Article

References (31)

1. Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint, and S. I. Hay. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217.
2. Sachs, J., and P. Malaney. 2002. The economic and social burden of malaria. Nature 415: 680-685.
3. Mahanty, S., A. Saul, and L. H. Miller. 2003. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. 206: 3781-3788.
4. Peterson, M. G., V. M. Marshall, J. A. Smythe, P. E. Crewther, A. Lew, A. Silva, R. F. Anders, and D. J. Kemp. 1989. Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol. Cell. Biol. 9: 3151-3154.
5. Remarque, E. J., B. W. Faber, C. H. Kocken, and A. W. Thomas. 2008. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24: 74-84.
6. Triglia, T., J. Healer, S. R. Caruana, A. N. Hodder, R. F. Anders, B. S. Crabb, and A. F. Cowman. 2000. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol. Microbiol. 38: 706-718.
7. Kato, K., D. C. Mayer, S. Singh, M. Reid, and L. H. Miller. 2005. Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. Proc. Natl. Acad. Sci. USA 102: 5552-5557. (Pubitemid 40530295)
8. Mitchell, G. H., A. W. Thomas, G. Margos, A. R. Dluzewski, and L. H. Bannister. 2004. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect. Immun. 72: 154-158.
9. Collins, W. E., D. Pye, P. E. Crewther, K. L. Vandenberg, G. G. Galland, A. J. Sulzer, D. J. Kemp, S. J. Edwards, R. L. Coppel, J. S. Sullivan, C. L. Morris, and R. F. Anders. 1994. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51: 711-719.
10. Deans, J. A., A. M. Knight, W. C. Jean, A. P. Waters, S. Cohen, and G. H. Mitchell. 1988. Vaccination trials in rhesus monkeys with a minor, invariant Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol. 10: 535-552.
11. Stowers, A. W., M. C. Kennedy, B. P. Keegan, A. Saul, C. A. Long, and L. H. Miller. 2002. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immun. 70: 6961-6967.
12. Polley, S. D., T. Mwangi, C. H. Kocken, A. W. Thomas, S. Dutta, D. E. Lanar, E. Remarque, A. Ross, T. N. Williams, G. Mwambingu, et al. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
13. Nebie, I., A. Diarra, A. Ouedraogo, I. Soulama, E. C. Bougouma, A. B. Tiono, A. T. Konate, R. Chilengi, M. Theisen, D. Dodoo, et al. 2007. Humoral responses to Plasmodium falciparum blood stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect. Immun. 76: 759-766.
14. Hodder, A. N., P. E. Crewther, and R. F. Anders. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69: 3286-3294.
15. Nair, M., M. G. Hinds, A. M. Coley, A. N. Hodder, M. Foley, R. F. Anders, and R. S. Norton. 2002. Structure of domain III of the blood-stage malaria vaccine candidate. Plasmodium falciparum apical membrane antigen 1 (AMA1). J. Mol. Biol. 322: 741-753.
16. Malkin, E. M., D. J. Diemert, J. H. McArthur, J. R. Perreault, A. P. Miles, B. K. Giersing, G. E. Mullen, A. Orcutt, O. Muratova, M. Awkal, et al. 2005. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73: 3677-3685.
17. Mullen, G. E., R. D. Ellis, K. Miura, E. Malkin, C. Nolan, M. Hay, M. P. Fay, A. Saul, D. Zhu, K. Rausch, et al. 2008. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3: e2940.
18. Giersing, B., K. Miura, R. Shimp, J. Wang, H. Zhou, A. Orcutt, A. Stowers, A. Saul, L. H. Miller, C. Long, and S. Singh. 2005. Posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate. Infect. Immun. 73: 3963-3970.
19. Mullen, G. E., B. K. Giersing, O. Ajose-Popoola, H. L. Davis, C. Kothe, H. Zhou, J. Aebig, G. Dobrescu, A. Saul, and C. A. Long. 2006. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24: 2497-2505.
20. Miura, K., H. Zhou, O. V. Muratova, A. C. Orcutt, B. Giersing, L. H. Miller, and C. A. Long. 2007. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect. Immun. 75: 5827-5836.
21. Dicko, A., D. J. Diemert, I. Sagara, M. Sogoba, M. B. Niambele, M. H. Assadou, O. Guindo, B. Kamate, M. Baby, M. Sissoko, et al. 2007. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE 2: e1045.
22. Guevara Patino, J. A., A. A. Holder, J. S. McBride, and M. J. Blackman. 1997. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 186: 1689-1699.
23. Nwuba, R. I., O. Sodeinde, C. I. Anumudu, Y. O. Omosun, A. B. Odaibo, A. A. Holder, and M. Nwagwu. 2002. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect. Immun. 70: 5328-5331.
24. 19, predicts protection from malaria infection and high-density parasitemia. Infect. Immun. 72: 1557-1567.
25. Howell, S. A., C. Withers-Martinez, C. H. Kocken, A. W. Thomas, and M. J. Blackman. 2001. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J. Biol. Chem. 276: 31311-31320.
26. Narum, D. L., and A. W. Thomas. 1994. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 67: 59-68.
27. Dutta, S., J. D. Haynes, J. K. Moch, A. Barbosa, and D. E. Lanar. 2003. Invasioninhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc. Natl. Acad. Sci. USA 100: 12295-12300. (Pubitemid 37271554)
28. Dicko, A., I. Sagara, D. Diemert, M. Sogoba, M. B. Niambele, A. Dao, G. Dolo, D. Yalcouye, D. A. Diallo, A. Saul, et al. 2007. Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. Am. J. Trop. Med. Hyg. 77: 1028-1033. (Pubitemid 351837787)
29. Miura, K., A. C. Orcutt, O. V. Muratova, L. H. Miller, A. Saul, and C. A. Long. 2008. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200. (Pubitemid 350266126)
30. Johnson, A. H., R. G. Leke, N. R. Mendell, D. Shon, Y. J. Suh, D. Bomba-Nkolo, V. Tchinda, S. Kouontchou, L. W. Thuita, A. M. van der Wel, et al. 2004. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1. Infect. Immun. 72: 2762-2771.
31. Biswas, S., R. K. Seth, P. K. Tyagi, S. K. Sharma, and A. P. Dash. 2008. Naturally acquired immunity and reduced susceptibility to falciparum malaria in two subpopulations of endemic eastern India. Scand. J. Immunol. 67: 177-184.